Clinical Trial Update: Pharmacokinetic Profile of Neupro Patch Administrated at 2 mg, 4 mg, 6 mg and 8 mg/Day Weekly in Patients With Early-stage Parkinson's Disease [Phase 1]

View source ↗

Summary

This Phase 1 pharmacokinetic study evaluates the rotigotine patch (Neupro) at weekly doses of 2, 4, 6, and 8 mg/day in patients with early-stage Parkinson's dis…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• Neupro (rotigotine)

Snippet

Sponsor: Luye Pharma Group Ltd. | Conditions: Parkinson's Disease | Phase 1 | Status: COMPLETED